Brokerages Set Amedisys, Inc. (NASDAQ:AMED) Price Target at $108.94

Posted by Defense World Staff on May 23rd, 2023

Amedisys, Inc. (NASDAQ:AMED – Get Rating) has been given an average rating of “Hold” by the eighteen brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and seven have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $108.94.

Several brokerages recently commented on AMED. StockNews.com assumed coverage on Amedisys in a report on Tuesday, May 16th. They set a “buy” rating on the stock. Barclays reduced their target price on shares of Amedisys from $93.00 to $88.00 in a research report on Friday, May 5th. Truist Financial decreased their target price on shares of Amedisys from $115.00 to $97.00 in a research note on Thursday, May 4th. Benchmark reaffirmed a “buy” rating and set a $115.00 price target on shares of Amedisys in a research note on Tuesday, March 14th. Finally, Stephens reissued an “equal weight” rating and issued a $103.00 price objective on shares of Amedisys in a research report on Tuesday, March 14th.

Amedisys Price Performance

AMED opened at $79.13 on Friday. Amedisys has a 52-week low of $69.36 and a 52-week high of $131.32. The company has a 50 day moving average of $76.75 and a two-hundred day moving average of $84.37. The company has a market cap of $2.58 billion, a P/E ratio of 23.00, a P/E/G ratio of 2.22 and a beta of 1.02. The company has a quick ratio of 1.15, a current ratio of 1.15 and a debt-to-equity ratio of 0.33.

Amedisys (NASDAQ:AMED – Get Rating) last announced its quarterly earnings results on Thursday, May 4th. The health services provider reported $1.00 earnings per share for the quarter, topping analysts’ consensus estimates of $0.86 by $0.14. Amedisys had a net margin of 5.02% and a return on equity of 14.35%. The firm had revenue of $556.39 million during the quarter, compared to analysts’ expectations of $558.98 million. During the same period in the prior year, the company earned $1.23 EPS. The firm’s revenue was up 2.0% on a year-over-year basis. On average, analysts expect that Amedisys will post 4.25 earnings per share for the current year.

Insider Transactions at Amedisys

In related news, insider Michael Paul North sold 5,908 shares of the company’s stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $86.43, for a total transaction of $510,628.44. Following the sale, the insider now directly owns 4,164 shares of the company’s stock, valued at approximately $359,894.52. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On Amedisys

Institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. grew its holdings in shares of Amedisys by 13.5% during the first quarter. JPMorgan Chase & Co. now owns 1,997,030 shares of the health services provider’s stock valued at $146,881,000 after purchasing an additional 237,160 shares during the last quarter. New York State Common Retirement Fund grew its holdings in shares of Amedisys by 8.6% during the first quarter. New York State Common Retirement Fund now owns 53,273 shares of the health services provider’s stock valued at $3,918,000 after purchasing an additional 4,204 shares during the last quarter. Thrivent Financial for Lutherans grew its position in shares of Amedisys by 179.1% during the first quarter. Thrivent Financial for Lutherans now owns 57,069 shares of the health services provider’s stock worth $4,197,000 after acquiring an additional 36,623 shares during the last quarter. Susquehanna International Group LLP grew its position in shares of Amedisys by 44.9% during the first quarter. Susquehanna International Group LLP now owns 22,656 shares of the health services provider’s stock worth $1,666,000 after acquiring an additional 7,024 shares during the last quarter. Finally, Segall Bryant & Hamill LLC grew its position in shares of Amedisys by 1.6% during the first quarter. Segall Bryant & Hamill LLC now owns 127,403 shares of the health services provider’s stock worth $9,370,000 after acquiring an additional 2,055 shares during the last quarter. Institutional investors own 96.17% of the company’s stock.

Amedisys Company Profile

(Get Rating)

Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery.